Safety and Tolerability of Nicotinamide Riboside in Heart Failure With Reduced Ejection Fraction
Key result
Nicotinamide riboside (1,000 mg twice daily) was safe, well tolerated, and doubled whole blood NAD+ levels, which correlated with increased PBMC basal respiration (R2=0.413, P=0.003).
Why the study?
Heart failure mitochondrial dysfunction is linked to changes in NAD+ and NADH levels, and raising NAD+ with nicotinamide riboside may represent a novel treatment.
Does nicotinamide riboside 1,000 mg twice daily safely increase NAD+ levels in patients with clinically stable heart failure with reduced ejection fraction?
Population
30 patients with clinically stable HF with reduced ejection fraction
Comparison
Nicotinamide riboside 1,000 mg twice daily
Design
Trial
Authors
Discussion
Loading...
Member takes
Implication
Supports testing nicotinamide riboside in stable HFrEF; hypothesis-generating and requires randomized outcome trials before practice change.
Structured PICO
Does nicotinamide riboside 1,000 mg twice daily safely increase NAD+ levels in patients with clinically stable heart failure with reduced ejection fraction?
P
Population
30 patients with clinically stable heart failure with reduced ejection fraction.
I
Intervention
Nicotinamide riboside 1,000 mg twice daily
O
Outcome
Safety, tolerability, and whole blood NAD+ levelssafety
Nicotinamide riboside safely doubles whole blood NAD+ levels and improves cellular respiration markers in patients with stable HFrEF, suggesting potential as a novel metabolic therapy.
Cite This Study
Wang et al. (2022) studied Heart failure with reduced ejection fraction (n=30). Nicotinamide riboside was evaluated on Safety, tolerability, and whole blood NAD+ levels. Nicotinamide riboside (1,000 mg twice daily) was safe, well tolerated, and doubled whole blood NAD+ levels, which correlated with increased PBMC basal respiration (R2=0.413, P=0.003).